Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.

Ray D. Page; Leylah Drusbosky; Hiba I. Dada; Victoria M. Raymond; Davey B. Daniel; Stephen G. Divers; Karen L. Reckamp; Miguel Angel Villalona-Calero; Justin Iver Odegaard; Richard B. Lanman; Vassiliki Papadimitrakopoulou; Natasha B. Leighl

doi:10.1200/JCO.2021.39.15_SUPPL.9027

Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.

Ray D. Page
, Leylah Drusbosky
, Hiba I. Dada
, Victoria M. Raymond
, Davey B. Daniel
, Stephen G. Divers
, Karen L. Reckamp
, Miguel Angel Villalona-Calero
, Justin Iver Odegaard
, Richard B. Lanman
, Vassiliki Papadimitrakopoulou
, Natasha B. Leighl

The Center for Cancer and Blood Disorders, Fort Worth, TX;
Guardant Health, Inc., Redwood City, CA;
Sarah Cannon Research Institute
Genesis Cancer Center, Hot Springs, AR;
Cedars-Sinai Medical Center
City of Hope National Medical Center
Lifecode, San Francisco, CA;
Pfizer
Princess Margaret Cancer Centre

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	39
DOIs	https://doi.org/10.1200/JCO.2021.39.15_SUPPL.9027
State	Published - May 20 2021
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2021.39.15_SUPPL.9027License: Unspecified

Cite this

Page, R. D., Drusbosky, L., Dada, H. I., Raymond, V. M., Daniel, D. B., Divers, S. G., Reckamp, K. L., Villalona-Calero, M. A., Odegaard, J. I., Lanman, R. B., Papadimitrakopoulou, V., & Leighl, N. B. (2021). Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma. Journal of Clinical Oncology, 39. https://doi.org/10.1200/JCO.2021.39.15_SUPPL.9027

Page, RD, Drusbosky, L, Dada, HI, Raymond, VM, Daniel, DB, Divers, SG, Reckamp, KL, Villalona-Calero, MA, Odegaard, JI, Lanman, RB, Papadimitrakopoulou, V & Leighl, NB 2021, 'Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.', Journal of Clinical Oncology, vol. 39. https://doi.org/10.1200/JCO.2021.39.15_SUPPL.9027

@article{37b33fa05a434fd7ab56eae6378bf92f,

title = "Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.",

author = "Page, \{Ray D.\} and Leylah Drusbosky and Dada, \{Hiba I.\} and Raymond, \{Victoria M.\} and Daniel, \{Davey B.\} and Divers, \{Stephen G.\} and Reckamp, \{Karen L.\} and Villalona-Calero, \{Miguel Angel\} and Odegaard, \{Justin Iver\} and Lanman, \{Richard B.\} and Vassiliki Papadimitrakopoulou and Leighl, \{Natasha B.\}",

note = "9027 Background: Somatic genomic testing is recommended by numerous expert guidelines to inform targeted therapy treatment for patients with advanced lung adenocarcinoma (aLUAD). The NILE study was a prospective observational study that demonstrated non-inferiority of cell-free circulating tumor DNA (cfDNA)-based tumor genotyping compared to tissue-based genotyping to find targetable genomic alterations in patients with newly diagnosed aLUAD.",

year = "2021",

month = may,

day = "20",

doi = "10.1200/JCO.2021.39.15\_SUPPL.9027",

language = "American English",

volume = "39",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.

AU - Page, Ray D.

AU - Drusbosky, Leylah

AU - Dada, Hiba I.

AU - Raymond, Victoria M.

AU - Daniel, Davey B.

AU - Divers, Stephen G.

AU - Reckamp, Karen L.

AU - Villalona-Calero, Miguel Angel

AU - Odegaard, Justin Iver

AU - Lanman, Richard B.

AU - Papadimitrakopoulou, Vassiliki

AU - Leighl, Natasha B.

N1 - 9027 Background: Somatic genomic testing is recommended by numerous expert guidelines to inform targeted therapy treatment for patients with advanced lung adenocarcinoma (aLUAD). The NILE study was a prospective observational study that demonstrated non-inferiority of cell-free circulating tumor DNA (cfDNA)-based tumor genotyping compared to tissue-based genotyping to find targetable genomic alterations in patients with newly diagnosed aLUAD.

PY - 2021/5/20

Y1 - 2021/5/20

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.9027

U2 - 10.1200/JCO.2021.39.15_SUPPL.9027

DO - 10.1200/JCO.2021.39.15_SUPPL.9027

M3 - Article

VL - 39

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.

Disciplines

Access to Document

Other files and links

Cite this